Company research
GERON CORP
CIK 886744Updated Sep 24, 2026
SecurityGERN · NASDAQ · equity
Historical securities (1)
GERNW · NASDAQ · warrant · closed Dec 30, 2025Name history
GERON CORPORATION · through Aug 5, 2005
GERN price & chart
Loading TradingView…
NASDAQ:GERN on TradingView ↗About the company
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. To learn more, visit www.geron.com or follow us on LinkedIn.
In the news
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
GERN Investors are Reminded of an Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm News provided by The Schall Law Firm May 12, 2025, 09:54 ET Share this article Share to X Share this article Share to X LOS ANGELES , May 12, 2025 /PRNewswire/ -- The Schall Law ↗
GERN Deadline: GERN Investors with Losses in Excess of $100K Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit News provided by THE ROSEN LAW FIRM, P. A. May 09, 2025, 14:45 ET Share this article Share to X Share this article Share to X NEW YORK , May 9, 2025 /PRNewswire/ -- Why: R ↗
Recent filings
SCHEDULE 13G/A filing
Results of Operations and Financial Condition
Items 2.02, 9.01
S-8 filing
10-Q filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 570,540,000Source | 593,781,000Source | 394,076,000Source | 190,575,000Source |
| Property, Plant and Equipment, NetUSD | 884,000Source | 1,310,000Source | 1,177,000Source | 793,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 77,560,000Source | 79,016,000Source | 70,023,000Source | 56,845,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 36,987,000Source | 35,946,000Source | — | — |
| Inventory, NetUSD | 116,636,000Source | 38,714,000Source | — | — |
| Assets, CurrentUSD | 520,271,000Source | 490,992,000Source | 341,348,000Source | 180,246,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,610,000Source | 5,053,000Source | 4,879,000Source | 3,992,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,151,000Source | 2,881,000Source | 3,556,000Source | 4,147,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 344,668,000Source | 313,461,000Source | 146,127,000Source | 110,577,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | — | — | — |
| Common Stock, Value, IssuedUSD | 640,000Source | 606,000Source | 545,000Source | 390,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,855,841,000Source | -1,772,341,000Source | -1,597,769,000Source | -1,413,642,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 269,000Source | 261,000Source | 185,000Source | -219,000Source |
| Stockholders' Equity Attributable to ParentUSD | 225,872,000Source | 280,320,000Source | 247,949,000Source | 79,998,000Source |
| Additional Paid in Capital, Common StockUSD | 2,080,804,000Source | 2,051,794,000Source | 1,844,988,000Source | 1,493,469,000Source |
| Liabilities and EquityUSD | 570,540,000Source | 593,781,000Source | 394,076,000Source | 190,575,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 111,542,000Source | 88,298,000Source | 108,070,000Source | 76,694,000Source |
| Operating Lease, Liability, CurrentUSD | 1,000,000Source | 974,000Source | 949,000Source | 925,000Source |
| Accounts Payable, CurrentUSD | 11,257,000Source | 8,595,000Source | 6,161,000Source | 10,190,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,445,000Source | 2,266,000Source | 3,006,000Source | 3,671,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 51,340,000Source | 35,549,000Source | 40,308,000Source | 33,100,000Source |
| Deferred Tax Liabilities, NetUSD | — | 682,000Source | 1,000,000Source | 1,100,000Source |
| Long-term Debt, Current MaturitiesUSD | — | — | 46,893,000Source | 20,945,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 119,547,000Source | 118,476,000Source | 35,051,000Source | 30,212,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | -174,572,000Source | -184,127,000Source | -141,901,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 26,659,000Source | 31,185,000Source | 18,526,000Source | 8,001,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 991,000Source | 35,695,000Source | — | — |
| Increase (Decrease) in InventoriesUSD | 77,922,000Source | 37,971,000Source | — | — |
| Increase (Decrease) in Accounts PayableUSD | 2,661,000Source | 2,435,000Source | -4,029,000Source | 3,503,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -111,037,000Source | -218,618,000Source | -167,743,000Source | -127,379,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 107,247,000Source | -106,004,000Source | -180,322,000Source | 62,067,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 680,000Source | 830,000Source | 431,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 2,267,000Source | 334,372,000Source | 362,021,000Source | 87,264,000Source |
| Repayments of Long-term DebtUSD | 0Source | 86,554,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -1,436,000Source | 9,738,000Source | 13,929,000Source | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 11,712,000Source | 10,364,000Source | -7,017,000Source | 5,154,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 87,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 25,443,000Source | 31,927,000Source | 18,525,000Source | 8,001,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 1,071,000Source | -3,108,000Source | 1,088,000Source | 1,327,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | 0Source | -1,707,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 69,135,000Source | 43,628,000Source |
| Income Tax Expense (Benefit)USD | 75,000Source | 449,000Source | — | — |
| InterestExpenseNonoperatingUSD | 32,657,000Source | — | — | — |
| Investment Income, InterestUSD | 18,117,000Source | 19,607,000Source | 18,152,000Source | 2,529,000Source |
| Net Income (Loss) Attributable to ParentUSD | -83,500,000Source | -174,572,000Source | -184,127,000Source | -141,901,000Source |
| Operating Costs and ExpensesUSD | 4,745,000Source | 1,256,000Source | — | — |
| Operating ExpensesUSD | 252,466,000Source | 250,726,000Source | 194,181,000Source | 139,146,000Source |
| Other Nonoperating Income (Expense)USD | -375,000Source | -236,000Source | -23,000Source | 1,002,000Source |
| Proceeds from Issuance of Long-term DebtUSD | 0Source | 121,120,000Source | 29,700,000Source | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | 371,608,000Source | 296,102,000Source | 320,505,000Source |
| Proceeds from Stock Options ExercisedUSD | 1,500,000Source | 31.6Source | 12,356,000Source | 1,799,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 26,747,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | — | 237,000Source | 596,000Source |
| Selling, General and Administrative ExpenseUSD | 159,256,000Source | 145,732,000Source | — | — |
| Operating Income (Loss)USD | -68,585,000Source | -173,732,000Source | -193,944,000Source | -138,550,000Source |
| Other Nonoperating Income (Expense)USD | -375,000Source | -236,000Source | -23,000Source | 1,002,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -83,425,000Source | -174,521,000Source | — | — |
| Income Tax Expense (Benefit)USD | 75,000Source | 449,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -83,500,000Source | -174,572,000Source | -184,127,000Source | -141,901,000Source |
| Earnings Per Share, BasicUSD per share | -0.13Source | -0.27Source | -0.32Source | -0.37Source |
| Earnings Per Share, DilutedUSD per share | -0.13Source | -0.27Source | -0.32Source | -0.37Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 666,662,989Source | 646,033,247Source | 570,645,405Source | 380,784,846Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 666,662,989Source | 646,033,247Source | 570,645,405Source | 380,784,846Source |
| Interest Expense (non-operating)USD | 32,657,000Source | — | — | — |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 474,000Source | 546,000Source | 442,000Source | 288,000Source |
| General and Administrative ExpenseUSD | — | — | 69,135,000Source | 43,628,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -82,358,000Source | -174,737,000Source | — | — |
| Interest ExpenseUSD | — | 18,504,000Source | 8,312,000Source | 6,882,000Source |
| Investment Income, InterestUSD | 18,117,000Source | 19,607,000Source | 18,152,000Source | 2,529,000Source |
| Operating Costs and ExpensesUSD | 4,745,000Source | 1,256,000Source | — | — |
| Operating ExpensesUSD | 252,466,000Source | 250,726,000Source | 194,181,000Source | 139,146,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 26,747,000Source | — | — | — |
Filing attachments
d158179dex991.htm · 8-K · 2026-08-06
EX-99.1 2 d158179dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights August 5, 2026 Achieved $57.5 million in RYTELO ® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended Q2 2026 with cash…
Read attachment ↗d67820dex991.htm · 8-K · 2026-02-25
EX-99.1 2 d67820dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights Achieved $48 million and $184 million in RYTELO ® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the previous guidance range Reiterated 2026 RYTELO net product revenue and total operating expenses expected in the ranges…
Read attachment ↗gern-ex99_1.htm · 8-K · 2025-02-26
EX-99.1 2 gern-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights Achieved $47.5 million in RYTELO™ (imetelstat) net product revenue in Q4 2024 and $76.5 million since commercial launch at the end of June 2024, following FDA approval Expect to reach profitability without additional financing if current internal sales and operating expenses expectations are met FOSTER CITY, Calif., February …
Read attachment ↗gern-ex99_1.htm · 8-K · 2025-01-13
EX-99.1 2 gern-ex99_1.htm EX-99.1 Corporate Presentation Our mission is to change lives by changing the course of blood cancer January 2025 Our mission is to change lives by changing the course of blood cancer Forward-Looking Statements Except for the historical information contained herein, this presentation contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements,…
Read attachment ↗